Disruption of Microtubules Sensitizes the DNA Damage-induced Apoptosis Through Inhibiting Nuclear Factor κB (NF-κB) DNA-binding Activity by Lee, Hyunji et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Disruption of Microtubules Sensitizes the DNA Damage-induced 
Apoptosis Through Inhibiting Nuclear Factor κB (NF-κB) 
DNA-binding Activity
The massive reorganization of microtubule network involves in transcriptional regulation of 
several genes by controlling transcriptional factor, nuclear factor-kappa B (NF-κB) activity. 
The exact molecular mechanism by which microtubule rearrangement leads to NF-κB 
activation largely remains to be identified. However microtubule disrupting agents may 
possibly act in synergy or antagonism against apoptotic cell death in response to 
conventional chemotherapy targeting DNA damage such as adriamycin or comptothecin in 
cancer cells. Interestingly pretreatment of microtubule disrupting agents (colchicine, 
vinblastine and nocodazole) was observed to lead to paradoxical suppression of DNA 
damage-induced NF-κB binding activity, even though these could enhance NF-κB signaling 
in the absence of other stimuli. Moreover this suppressed NF-κB binding activity 
subsequently resulted in synergic apoptotic response, as evident by the combination with 
Adr and low doses of microtubule disrupting agents was able to potentiate the cytotoxic 
action through caspase-dependent pathway. Taken together, these results suggested that 
inhibition of microtubule network chemosensitizes the cancer cells to die by apoptosis 
through suppressing NF-κB DNA binding activity. Therefore, our study provided a possible 
anti-cancer mechanism of microtubule disrupting agent to overcome resistance against to 
chemotherapy such as DNA damaging agent.
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ORIGINAL ARTICLE
Pharmacology, Drug Therapy & Toxicology
INTRODUCTION
The nuclear factor κB (NF-κB) is a rapidly inducible transcrip-
tion factor involved in regulating the expression of genes rele-
vant in wide range of different cellular processes including apop-
tosis, cell survival and immune response (1, 2). In most types of 
cells, inactive NF-κB is retained in the cytoplasm through its in-
teraction with the inhibitory proteins known as IκBs (1). Upon 
activation by various stimuli, such as proinflammatory cytokines, 
ionizing radiation (IR), DNA damaging agents and cellular stress, 
IκBs are phosphorylated by the IκB kinase (IKK) complex, and 
rapidly degraded by the proteasome after polyubiquitination, 
resulting in NF-κB translocation into the nucleus (3, 4). Accu-
mulating evidence indicates that NF-κB plays a critical role in 
cellular protection against to various anticancer drugs- or IR-
induced apoptosis, and therefore suggested that the activation 
NF-κB may contribute in blocking the efficacy of cancer thera-
pies and radiation (5-7). Indeed, inhibition of NF-κB leads to 
sensitization of apoptotic cell death in response to IR or DNA 
damaging agents in large number of cancer cells (8-10). Further-
more, aberrant dysregulation of NF-κB activity or increased nu-
clear level of NF-κB subunit (RelA/p50) has been commonly 
observed in several solid tumors and hematopoietic malignan-
cies, and chemoresistance in selected tumors has been linked 
to the activated NF-κB status (11-13). Therefore, selective sup-
pression of NF-κB will provide a useful strategy for overcoming 
drug-resistance in patients treated with conventional chemo-
therapy. 
  In addition to DNA-damaging agents, it has been previously 
reported that massive microtubule reorganization by microtu-
bule disrupting agents such as cytochalasins or nocodazole ac-
tivates NF-κB and induces NF-κB dependent gene expression 
(14, 15). So far, although the exact molecular mechanism by 
which microtubule disrupting agents leads to activation of NF-
κB remains to be elucidated, the sensing changes in the state of 
cytoskeleton may be one of way to regulate NF-κB signaling path-
way. Relevant to this issue, microtubule system has recently been 
identified as an important regulator of translocation of the ac-
tive NF-κB from cytosol to the nucleus (16, 17). Thus, it is possi-
ble that the disruption of microtubule could be important regu-Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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lator for DNA damage-induced NF-κB activation, or acts in syn-
ergy to sensitize the apoptotic response against to chemothera-
peutic agents.  
  Here we report that disruption of microtubule inhibits DNA 
damage-induced NF-κB binding activity without alteration of 
nuclear translocation of NF-κB subunit, even though it can en-
hance NF-κB activation in the absence of other signals. Further-
more, such suppressed NF-κB binding activity by combined treat-
ment of microtubule disrupting agent was correlated with the 
sensitization effect of apoptotic response to DNA damage agents. 
These results support the idea that, the combined treatment of 
these compounds could have a synergic potential use in cancer 
therapy to overcome NF-κB mediated resistance.  
MATERIALS AND METHODS
Cells
Human cervical cancer epithelial cells HeLa (American Type 
Culture Collection, CCL-2, Bethesda, MD, USA) and mouse em-
bryonic fibroblasts (MEF) cells, including wild-type and p65-/- 
cells (kindly donated by Dr Zhengang Liu; Center for Cancer 
Research, National Cancer Institute, Bethesda, MD, USA) were 
cultured in Dulbecco's modified Eagle's medium supplement-
ed with 10% fetal bovine serum, 2 mM glutamine, antibiotics 
(100 U/mL penicillin G and 100 µg/mL streptomycin), and 10% 
heat-inactivated FBS and were maintained at 37°C in a humidi-
fied incubator containing 5% CO2. 
Reagents 
All commercial antibodies were purchased from the following: 
anti-IKKβ (Upstate Biotech, Waltham, MA, USA); anti-p84N5 
(GeneTex, Irvine, CA, USA); anti-actin (Sigma-Aldrich, St. Lou-
is, MO, USA); anti-phospho-IκB-α, anti-caspase-3 and anti-cas-
pase-9 (Cell Signaling Technology, Beverly, MA, USA); anti-IκB- 
α, anti-p65, anti-tubulin, anti-SP1 (Santa Cruz Biothenology, 
Santa Cruz, CA, USA), anti-poly (ADP-ribose) polymerase (PARP) 
(BD Biosciences Pharmingen, San Diego, CA, USA). Cochicine 
(Col) were purchased from Sigma-Aldrich. Trypan blue was 
purchased from Cambrex Bio Science (Walkersville, MD, USA). 
Adriamycin (Adr), camptothcin (Cpt), nocodazole (Noc), vin-
blastine (Vin), the NF-κB inhibitor BAY-11, the selective inhibi-
tor of IKK-β 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-
thiophenecarboxamide (TPCA-1) and the pancaspase inhibitor 
Z-VAD-FMK were purchased from Calbiochem (San Diego, CA, 
USA). Poly(dI-dC)•poly(dI-dC) and dNTP were purchased from 
Pharmacia LKB Biotechnology. [α-
32P]dCTP was purchased from 
Amersham (Piscataway, NJ, USA).
Western blot analysis 
After treatment with different reagents as described in the Fig-
ure legends, cells were collected and lysed in M2 buffer (20 mM 
Tris at pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM 
EGTA, 2 mM DTT, 0.5 mM PMSF, 20 mM β-glycerol phosphate, 
1 mM sodium vanadate, 1 µg/mL leupeptin). Fifty micrograms 
of the cell lysates were subjected to SDS-polyacrylamide gel and 
blotted onto PVDF membrane. After blocking with 5% skim milk 
in PBS/T, the membrane was probed with the relevant antibody 
and visualized by enhanced chemiluminescence (ECL), accord-
ing to the manufacturer’s instruction (Amersham).
Preparation of nuclear extracts
Nuclear extracts from whole cell extracts were prepared as de-
scribed elsewhere (18), with minor modifications. In brief, after 
treatment with different reagents as described in the figure leg-
ends, cells were centrifuged (1,500 rpm, 5 min, 4°C) and sus-
pended in ice-cold buffer A (10 mM HEPES pH 7.9; 10 mM KCl; 
0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; 0.5 mM phenylmeth-
anesulfonyl fluoride [PMSF]) and 0.5% NP-40 for 30 min, and 
then centrifuged (12,000 rpm, 10 min, 4°C) to separate the cyto-
solic fraction (supernatant) and nucleus fraction (pellet). The 
nucleus fraction was re-suspended in ice-cold buffer C (20 mM 
HEPES, pH 7.9; 400 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM 
DTT; 1 mM PMSF; 20% glycerol) for 30 min, and centrifuged at 
12,000 rpm for 10 min, 4°C. Protein concentration was estimat-
ed using the Bio-Rad protein assay reagent and an equal amount 
of proteins per sample of nuclear extract was further analyzed 
by SDS-PAGE and EMSA. 
Electrophoretic mobility shift assay (EMSA)
EMSA was performed as described previously (18). Briefly, 5 μg 
of nuclear extract was incubated at room temperature for 20 min 
with reaction buffer containing 20 mM HEPES, pH 7.9, 50 mM 
KCl, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 200 μg/mL BSA, 
and 2 μg of poly(dI-dC)•poly(dI-dC). Then the 
32P-labeled dou-
ble-stranded oligonucleotide (1 ng, ≥1×10
5 cpm) containing the 
NF-κB binding consensus sequence (5´-GGCAACCTGGGG-
ACTCTCCCTTT-3´) was added to the reaction mixture for an 
additional 10 min at room temperature. The reaction products 
were fractionated on a nondenaturating 6% polyacrylamide gel, 
which was then dried and subjected to autoradiography. West-
ern blot analysis with antibody against SP1 was also performed 
in the same nuclear extract as a control protein input. 
Determination of cell death 
Cells were seeded in six-well plates and treated with the indi-
cated concentrations of reagents as described in the figure leg-
ends. Cell death, as observed by microscopy, was characterized 
by rounding up and detaching of the cells from the plates. Cell 
death was quantified by trypsinization, followed by staining with 
trypan blue and counting with a hemocytometer (American 
Optical, New York, NY, USA). The stained cells (blue) were count-
ed as dead cells and were expressed as a percentage of cells. For Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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each treatment, triplicate experiments were performed.
Statistical analysis
Data are expressed as the mean±S.E. from at least three separate 
experiments performed. The differences between groups were 
analyzed using a Student’s t test, and P<0.05 is considered sta-
tistically significant. Statistical analyses were carried out using 
SPSS software (ver. 11.0; SPSS Inc., Chicago, IL, USA).  
RESULTS
Activation of NF-κB by microtubule disrupting agents
To characterize the NF-κB signaling pathway in HeLa cells af-
fected by the disruption of the microtubule network, we com-
pared the kinetics of the degradation of IκB-α at various time 
points after tumor necrosis factor (TNF) or tubulin polymeriza-
tion inhibitors (colchicine, vinblastine and nocodazole). As 
shown in the bottom panel of Fig. 1A, when cells were treated 
	 -	 0.5	 1	 3	 6	 12
Col	(hr)
	 -	 15	 30	 60 TNF	(min)
	 -	 0.5	 1	 3	 6	 12
Vin	(hr)








	 -	 0.25	 0.5	 1	 3	 6
Col	(hr)
	 -	 5	 15	 30	 60	 90 TNF	(min)
	 -	 0.25	 0.5	 1	 3	 6
Vin	(hr)







	 -	 0.25	 0.5	 1	 3	 6
Col	(hr)
	 -	 0.25	 0.5	 1	 3	 6
Vin	(hr)





Fig. 1. Microtubule disrupting agents induces NF-κB activation through nuclear translocation of NF-κB subunit p65. (A) HeLa cells were treated with microtubule disrupting 
agents (upper panel) including colchicines (Col, 10 μM), vinblastine (Vin, 1 μM) and nocodazole (Noc, 0.5 μM) or TNF (lower panel) for various times as indicated. Cell extracts 
were applied to SDS-PAGE for immunoblotting with anti-IκB-α and anti-p65 antibodies. As a protein loading control, the same amounts of extracts were analyzes by immunoblotting 
with anti-IKK-β antibody. (B, C) After HeLa cells were treated with 10 μM of Col, 1 μM of Vin or 0.5 μM of Noc for various times as indicated, nuclear extracts were obtained as 
described under Materials and Methods. (B) The nuclear translocation of NF-κB subunit p65 was analyzed by immunoblotting with anti-p65 and anti-p84N5 antibodies from 
nuclear extracts from each sample. (C) EMSAs were performed with labeled NF-κB oligomers and 5 μg of nuclear extracts to analyze NF-κB binding activity. As a control, 50 μg 
of the nuclear extracts were applied to SDS-PAGE for immunoblotting with anti-SP1 antibody.Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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with TNF, the expression of IκB-α started to be degraded at 15 
min after treatment, and was recovered by 60 min. In contrast to 
the cells treated with TNF, the IκB-α degradation and its recov-
ery were slower and weaker upon treatment with the microtu-
bule disrupting agents (top three panels of Fig. 1A), which sug-
gest that disruption of the microtubule network affects NF-κB 
activity in a different manner with a classical pathway. Since the 
nuclear translocation of NF-κB subunit, relA (p65) is essential 
for the NF-κB signaling pathway, we next examined the effect of 
the microtubule disrupting agents on the nuclear translocation 
of p65. As expected, the treatment of microtubule disrupting 
agents resulted in enhanced translocation of p65 into the nu-
cleus, even though the extent of accumulated p65 into nucleus 
was lower than that of TNF treatment (Fig. 1B). As previously 
reported (19), the expression of nuclear protein encoded by N5 
gene (p84N5) occurred principally in the nuclear fraction (Fig. 
1B, bottom panels). However, the expression levels of p65 on 
the total cell extract were unaffected by treatment with micro-
tubule disrupting agents (Fig. 1A). To confirm these observa-
tions, nuclear extracts were examined for NF-κB binding activi-
ty by EMSA using a palindromic NF-κB binding site. Consistent 
with above results, the binding activity of NF-κB subunit com-
plex was gradually increased in response to microtubule agents, 
indicating that microtubule disruption directly induce NF-κB 
binding activity through nuclear translocation of NF-κB sub-
unit, p65 without the expressional change of NF-κB. As a con-
trol of nuclear protein contents, the SP-1 protein level was ex-
amined by immunoblotting with an anti-SP-1 antibody and no 
difference was observed (Fig. 2B, bottom panels).    
Microtubule disrupting agents suppress the DNA damage-
induced NF-κB binding activity
Previous studies have demonstrated that the DNA damage trig-
ger a cytoplasmic signaling that leads to the activation of IKK 
and NF-κB, which is associated predominantly with protecting 
cells from apoptosis (6, 7). Therefore it is a possibility that NF-κB 
activation by DNA damaging agents could be responsible for 
the development for the chemoresistance. We next examined 
whether the DNA damage-induced NF-κB activation is affected 
by the disruption of microtubule network. Two DNA damaging 
NF-κB
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Fig. 2. DNA damaging agents induces NF-κB activation. (A) HeLa cells were treated with adriamycin (Adr, 10 μg/mL) or comptothecin (Cpt, 100 μM) for various times as indicated. 
Cell extracts were applied to SDS-PAGE for immunoblotting with anti-IκB-α and anti-IKK-β antibodies. (B) HeLa cells were treated as described in A for various times as indicated. 
Nuclear extracts were prepared and 5 μg of nuclear extracts from each sample was used to analyze NF-κB binding activity by EMSA with a NF-κB probe.
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Fig. 3. Microtubule disrupting agents suppresses the DNA damage-induced NF-κB 
binding activity. HeLa cells were treated with Adr (10 μg/mL) or Cpt (100 μM) for 
various times as indicated in the presence or absence of Col (A, 10 μM), Vin (B, 1 μM) 
and Noc (C, 0.5 μM). Nuclear extracts were prepared and 5 μg of nuclear extracts 
from each sample was used to analyze NF-κB binding activity by EMSA as described 
in Fig. 2B. As a control, 50 μg of the nuclear extracts were applied to SDS-PAGE for 
immunoblotting with anti-SP1 antibody.Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
1578   http://jkms.org DOI: 10.3346/jkms.2010.25.11.1574
agents, adriamycin (Adr) and comptothecin (Cpt), were used to 
detect the degradation of IκB-α and NF-κB binding activity in 
total cell extract and nuclear extract respectively. As similar to 
the effect of microtubule disrupting agents, Adr and Cpt in-
duced a slow and sustained degradation of IκB-α protein until 
after 9 h of treatment (Fig. 2A). Consistently, an increase in NF-
κB binding activity in response to Adr or Cpt treatment was evi-
dent, and the kinetics of NF-κB binding activity were correlated 
well with the IκB-α degradation (Fig. 2B, top panels). 
  Recent reports (16, 17) support the notion that microtubule 
network may play an important role for nuclear translocation of 
NF-κB subunits even though the microtubule disruption para-
doxically induced NF-κB activation (Fig. 1). To examine the issue 
whether microtubule integrity affect the DNA damage-induced 
NF-κB activation, we evaluated the NF-κB binding activity at dif-
ferent time points under the condition of microtubule disrup-
tion. Interestingly, pretreatment with Col, Vin or Noc dramati-
cally suppressed either Adr- or Cpt-induced NF-κB binding ac-
tivities (Fig. 3), indicating that functional microtubule network 
is required for the DNA binding activity. We also confirmed that 
TNF-induced NF-κB DNA binding activity was suppressed by 
pretreatment with these microtubule disrupting agents (Data 
not shown). 
  Because the above results clearly demonstrated that micro-
tubule disrupting agents suppressed the DNA damage-induced 
NF-κB DNA binding activity, we subsequently examined wheth-
er these agents affect the IκB-α degradation and nuclear trans-
location of p65 induced by DNA damage. Surprisingly, there was 
detectable degradation of IκB-α protein in response to Adr- or 
Cpt treatment under the condition of microtubule disruption 
(Fig. 4A, B). Furthermore pretreatment with Col, Vin or Noc 
failed to block the Adr- or Cpt-induced nuclear translocation of 
p65 (Fig. 4C, D). These data suggest that microtubule assembly 
has an important role for DNA damage-induced NF-κB binding 
activity at the level of nucleus but not at the cytoplasmic event.
Microtubule disrupting agents sensitizes DNA damage-
induced apoptotic cell death
Previous study has reported that DNA damaging agents such as 
Adr or Cpt can directly induce apoptosis in human cancer cells 
(20). The nature of DNA damage-induced cell death was as-
sessed by the activation of the caspase cascade, including cas-
pase-9 and -3 and resultant cleavage of PARP. Caspase-9, -3 and 
PARP were processed after Adr treatment, as shown by the deg-
radation of inactive pro-enzymes in a time-dependent manner 
(Fig. 5A, top three panels). Moreover, the increased processing 
of caspase cascade by Adr was completely abolished by pretreat-
ment with Z-VAD-FMK, a membrane permeable pancaspase 
inhibitor (Fig. 5A, fifth row), indicating that the activation of cas-
pase cascade plays an important role in DNA damage-induced 
apoptotic cell death in HeLa cell. Because NF-κB has been im-
plicated in apoptosis, we further examined whether the activa-
tion of NF-κB plays a role in DNA damage-induced cell death 
by comparing the responses of wild-type (WT) and p65-null 
(p65-/-) MEF cells. As shown in Fig. 5B, the extent of cell death 
was much higher in p65-/- MEF cells than in WT MEF cells mea-
sured by trypan blue exclusion assays. To ensure that p65 expres-
sion is indeed defective in p65-/- MEF cells, the expression lev-
els of p65 and IKK-β in WT and p65-/- MEF cells are examined 
(Fig. 5C). Furthermore, pretreatment of HeLa cells with NF-κB-
specific inhibitor Bay-11 and TPCA-1 before Adr exposure dra-
matically enhanced Adr-induced cell death (Fig. 5D). These re-
sults clearly indicate that NF-κB activation provides an impor-
tant anti-apoptotic role in DNA damage-induced cell death.
  To determine whether inhibition of NF-κB binding activities 
by microtubule disruption leads to sensitization of cytotoxic re-
sponse against DNA damaging agent, HeLa cells were pretreat-
ed with microtubule disrupting agents for 30 min followed by 
Adr, and cell viability was observed with a inverted light micro-
scope and trypan blue exclusion assay. As shown in Fig. 5E, 
pretreatment with Col, Vin and Noc markedly enhanced Adr-
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Fig. 4. Microtubule disrupting agents does not affect the DNA damage-induced IκB-α degradation and nuclear translocation of NF-κB subunit p65. HeLa cells were treated 
with Adr (10 μg/mL) or Cpt (100 μM) for various times as indicated in the presence or absence of Col (10 μM), Vin (1 μM) and Noc (0.5 μM). (A, B) Total cell extracts were 
prepared and applied to SDS-PAGE for immunoblotting with anti-IκB-α and anti-IKK-β antibodies. (C, D) Nuclear extracts were obtained as described Fig.1B, and the nuclear 
translocation of NF-κB subunit p65 was analyzed by immunoblotting with anti-p65 and anti-p84N5 antibodies from nuclear extracts (50 μg) from each sample.Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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observed in Z-VAD-FMK pretreated cells. The quantification of 
time-dependent cell death was summarized in Fig. 5F. Data 
suggested that microtubule disruption greatly sensitized DNA 
damage-induced apoptotic cell death. Furthermore, the com-
bined treatment of microtubule disrupting agents and Adr sig-
nificantly enhanced the cleavage of both caspase-9 and casa-
pse-3 as evidenced by the decrease of procaspase-9 and in-
crease of the active forms of caspase-3 (p21 fragment) (Fig. 5G, 
top two panels). A time-dependent enhancement of PARP cleav-
age was also detected in cells co-treated with microtubule dis-
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Fig. 5. Microtubule disrupting agents sensitizes DNA damage-induced apoptotic cell death. (A) HeLa cells were treated with Adr (10 μg/mL) for various times as indicated in the 
presence or absence of pan-caspase inhibitor z-VAD-FMK (20 μM) and cell extracts were analyzed by immunoblotting with antibodies against casapse-9, -3 and PARP. As a 
protein loading control, the same amounts of extracts were analyzes by immunoblotting with anti-actin antibody. The asterisks indicate cleaved products of casapse-3 and PARP 
upon Adr treatment. (B) Wild-type and p65-/- MEF cells were treated with various concentrations of Adr as indicated. 12 hr after treatment, the percentage of cell death was 
determined by trypan blue exclusion assay as described under Materials and Methods. The results represent the mean values of at least three independent experiments. *, P< 
0.05, compared with Adr-treated wild-type MEF cells. (C) The expression levels of p65 and IKK-β in wild-type and p65-/- MEF cells. The equal amount of cell extract from each 
cells was analyzed by immunoblotting with antibodies against p65, IKK-β and actin. (D) HeLa cells were pretreated with the NF-κB specific inhibitors, 5 μM Bay-11 or 1 μM 
TPCA-1 for 30 min and then treated with 10 μg/mL Adr for 12 hr. Cell death was quantified as described in (B), and each column shows mean±S.E. of at least three independent 
experiments. *, P<0.05, compared with Adr-treated group. (E) HeLa cells were treated with Adr (10 μg/mL) for 15 hr in the presence or absence of Col (10 μM), Vin (1 μM) and 
Noc (0.5 μM), or z-VAD-FMK (20 μM). Then, cells were visualized with a normal light microscope with an inverted microscope. (F) HeLa cells were treated with Adr (10 μg/mL) 
for various times as indicated in the presence or absence of Col (10 μM), Vin (1 μM) and Noc (0.5 μM). Cell death was quantified as described in (B), and each column shows 
mean±S.E. of at least three independent experiments. (G) HeLa cells were treated as described in (C). Cell extracts form each sample were analyzed by SDS-PAGE followed by 
immunoblotting with antibodies against casapse-9, -3, PARP and actin. The asterisks indicate cleaved products of casapse-3 and PARP.Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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rupting agents and Adr (Fig. 5G, third panel). Thus these results 
indicate that microtubule disrupting agents are able to sensitize 
DNA damage-induced apoptosis via promoting the caspase 
cascade. 
DISCUSSION
It has been well established that the activity of NF-κB can be in-
duced by IR or some conventional chemotherapeutic agents 
including Adr, etoposide, Cpt, vinca alkaloids and taxol (4, 15). 
Once activated by those stress, NF-κB has been shown to sup-
press the apoptotic potential of the chemotherapy in several 
cancer cells and in vivo cancer model (21, 22). Thus it has been 
widely proposed that activation of NF-κB in response to che-
motherapy could be a potential mechanism of inducible che-
moresistance which protects cancer cells from apoptotic stress. 
As documented previously, anti-carcinogenic property of DNA 
damaging agents such as Adr and Cpt is closely associated with 
an activation of tumor suppressor gene p53 which results in lim-
ited cell proliferation and mitochondrial dependent apoptosis 
through transcriptionally activating p53 target genes (23, 24). In 
accordance with previous observations in a variety of tumor cell 
lines, we found that Adr-induced apoptosis in HeLa cells ap-
peared to accompany the activation of caspase-9 and -3, and 
subsequent PARP cleavage (Fig. 5A), which indicate a promi-
nent role for mitochondria in Adr-induced cell death. In the in-
trinsic mitochondrial apoptotic pathway, p53-target gene prod-
ucts including Bax and Bak are involved in the release of cyto-
chrome c, resulting in activation of caspase-9, which in turn ac-
tivates execution-type caspase-3 (25, 26). In contrast to p53-me-
diated apoptotic response, DNA damaging agents also activates 
NF-κB signaling pathway which can suppress mitochondrial-
dependent apoptotic pathway through transcriptional induc-
tion of anti-apoptotic genes including Bcl2. In addition, a num-
ber of factors including changes in cellular levels of P-glycopro-
tein family of multi- drug resistance (MDR), detoxification en-
zymes (e.g., glutathione S-transferase), DNA repair enzymes 
(e.g., DNA topoisomerase II), various oncogenes and mutated 
p53 have associated with development of cancer chemoresis-
tance (27, 28). In this study, NF-κB subunit (p65) null MEF cells 
were found to be much more resistant to cell death as compared 
with wild-type cells, which suggest that NF-κB plays a role in 
blocking the efficacy of chemotherapy with DNA damaging 
agents (Fig. 5B). This interpretation is further supported by our 
observation that the inhibition of NF-κB using Bay-11 and TPCA-
1 led to a dramatic enhanced cell death induced by Adr in HeLa 
cells (Fig. 5D). Although the further studies will be required to 
elucidate the exact molecular mechanisms of cancer chemore-
sistance, our study clearly raises the possibility that NF-κB could 
functions as an anti-apoptotic mediator in response to DNA 
damage. Consistent with this conclusion, there are some evi-
dences that the combinational chemotherapies to inhibit NF-
κB activation, including the administration of proteasome-spe-
cific inhibitors such as velcade, MG132 or some antioxidants 
such as N-acetylcystein provide a chemosensitization against 
DNA damage-induced killing (5). 
  In addition to DNA damaging agents, previous studies re-
ported that microtubule disrupting agents can enhance the NF-
κB dependent transcriptional activity presumably through the 
increased activity of protein kinase C (14, 29). Consistently we 
have also confirmed that Col, Vin and Noc have all been shown 
to activate NF-κB (Fig. 1). However, it has been recently proposed 
that the state of microtubule polymerization may also be crucial 
in the translocation of the active NF-κB subunit from cytosol to 
the nucleus. For instance, disruption of microtubule function 
by pretreatment with Col or Vin impaired accumulation and 
subsequent binding activities of NF-κB subunit p65 and p50 in 
the nucleus following glutamate stimulation (30) or zinc defi-
cient cells which caused deficit to tubulin polymerization (16). 
Based on these observations, we speculated that the combined 
treatment of microtubule disrupting agents affected the nuclear 
targeting of NF-κB by DNA damage. Interestingly, nuclear trans-
location of NF-κB subunit p65 in response to DNA damage was 
not affected after pretreatment with microtubule disrupting 
agents in our experimental conditions (Fig. 4C, D). Similarly, 
Mikenberg et al. (30) have shown that microtubule perturbing 
compounds did not affect TNF-induced nuclear accumulation 
of p65 by using confocal microscopy. These results strongly sug-
gest that NF-κB movement activated by either DNA damage or 
TNF is independent of cytoskeleton-based transport system in 
non-neuronal cancer cells. Despite these insights, we found that 
the microtubule disruption with Col, Vin and Noc led to drasti-
cally suppressed DNA damage-induced NF-κB binding activity 
by EMSA using nuclear extracts (Fig. 3), suggesting that the func-
tional microtubule network is required for the DNA binding ac-
tivity rather than the nuclear translocation of activated NF-κB 
subunit p65. Furthermore, we also found a significant increase 
in caspase-dependent apoptotic cell death after Adr treatment 
under the condition of microtubule disruption (Fig. 5E-G), sug-
gesting that the suppressed NF-κB binding activity by the com-
bined therapy may contribute to sensitize to trigger apoptotic 
machinery. 
  Taken together, data from this study collectively suggest that 
inhibition of microtubule network significantly chemosensitizes 
the cancer cells to die by apoptosis through suppressing NF-κB 
DNA binding activity. However, further study elucidating the 
molecular mechanism of microtubule disrupting agents on the 
regulation of NF-κB DNA binding activity in the nucleus will be 
critical for improving the value in the clinical application of these 
combined chemotherapies.Lee H, et al.  •  Microtubule Network in DNA Damage-induced NF-κB Binding Activity
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